A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.

Florence AtrafiHarry J M GroenLauren A ByersElena GarraldaMartijn P LolkemaRandeep S SanghaSantiago ViteriYoung Kwang ChaeD Ross CamidgeNashat Y GabrailBeibei HuTian TianSilpa NuthalapatiElizabeth HoeningLei HePhilip KomarnitskyAntonio Calles

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Veliparib (240 mg b.i.d. 14 days) plus carboplatin/etoposide can be safely combined. Phase II of this study is ongoing in first-line patients with ED SCLC.

Keyphrases

small cell lung cancer
phase ii
clinical trial
open label
emergency department
randomized controlled trial
squamous cell carcinoma
phase ii study
study protocol
brain metastases